<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The prognosis of chromosome 17 (chr17) abnormalities in patients with primary <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) remains unclear </plain></SENT>
<SENT sid="1" pm="."><plain>The revised International Prognostic Scoring System (IPSS-R) includes these abnormalities within the intermediate cytogenetic risk group </plain></SENT>
<SENT sid="2" pm="."><plain>This study assessed the impact on overall survival (OS) and risk of <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> transformation (AMLt) of chr17 abnormalities in 88 patients with primary <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>We have compared this group with 1346 patients with primary <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> and abnormal karyotype without chr17 involved </plain></SENT>
<SENT sid="4" pm="."><plain>The alterations of chr17 should be considered within group of poor prognosis </plain></SENT>
<SENT sid="5" pm="."><plain>The different types of alterations of chromosome 17 behave different prognosis </plain></SENT>
<SENT sid="6" pm="."><plain>The study confirms the intermediate prognostic impact of the i(17q), as stated in IPSS-R </plain></SENT>
<SENT sid="7" pm="."><plain>The results of the study, however, provide valuable new information on the prognostic impact of alterations of chromosome 17 in complex karyotypes </plain></SENT>
</text></document>